T cells (all obtained from C57BL/6 mice). Langerhans cells remained of host origin for at least 12 months after transplantation of a purified population of allogeneic stem cells or TCD bone marrow (Fig. 1a) . By contrast, host Langerhans cells were largely replaced by donor-derived Langerhans cells when we added donor T cells to the TCD bone marrow graft or when we transplanted whole bone marrow, which contains ∼2% mature T cells 12 (Fig. 1a) . These results suggest that alloreactive T cells are required for the recruitment of circulating donor Langerhans cell precursors to the skin. Other DC populations, however, were replaced by donor cells by 4 weeks after transplantation, whether or not the graft contained T cells (Fig. 1b) . Allogeneic T cells obtained from bone marrow, spleen or peripheral blood were equally able to induce Langerhans cell chimerism (Fig. 1c) , and they did so in a dose-dependent manner (Fig. 1d,e) . Consistent with other reports 4 , we observed skin GVHD only in mice that received donor T cells together with their grafts (data not shown).
Role of cytotoxic T cells in Langerhans cell chimerism
To explore whether cytotoxic T cells are required for Langerhans cell chimerism, we transplanted BALB/c mice with C57BL/6 TCD bone marrow supplemented with peripheral blood wild-type T cells, T cells deficient for the perforin cytotoxic-dependent pathway (Prf1 -/-) or Fas ligand-defective T cells isolated from mice homozygous for the generalized lymphoproliferative disease (gld) mutation. Prf1 -/-T cells, like wild-type T cells, induced complete depletion of host Langerhans cells by week 5 after transplantation, followed by strong recruitment of donor-derived Langerhans cells (Fig. 2a,b) . By contrast, gld T cells were substantially less efficient at inducing host Langerhans cell depletion; 40-60% of host Langerhans cells were still present in the skin 5 weeks after transplantation (Fig. 2a,b) . The extent of Langerhans cell chimerism induced by gld T cells was lower than that induced by wild-type or Prf1 -/-T cells (Fig. 2a,b) . All T-cell populations, including gld T cells, were able to infiltrate the skin of BALB/c recipient mice (Fig. 2c) , but mice that received gld T cells experienced less skin GVHD compared with those that received Prf1 -/-or wild-type T cells (Fig. 2d-g ).
Lymph node DC chimerism after allogeneic transplantation
To assess whether the persistence of host Langerhans cells in the skin leads to the persistence of dendritic cells in the draining lymph nodes, we analyzed the proportion of remaining host dendritic cells in skin and non-skin-draining lymph nodes of recipient mice. Four months after transplantation, mice with no Langerhans cell chimerism (TCD bone marrow recipients) or partial Langerhans cell chimerism (TCD bone marrow + gld T-cell recipients) had a higher proportion of host dendritic cells in skin-draining (inguinal) lymph nodes (20% and 3%, respectively, of the total inguinal DC population), compared with mesenteric lymph nodes from the same mice or skin-draining lymph nodes from mice that received wild-type (0.4%) or Prf1 -/-T cells (0.3%; Fig. 2h ). These differences persisted 8 months after transplantation (Fig. 2h) .
Skin chemokine profile
We have shown that the proinflammatory chemokines CCL2 (monocyte chemoattractant protein-1; MCP-1) and CCL7 (MCP-3) have a major role in the rapid trafficking of circulating Langerhans cell precursors to injured skin 11 . CCL20 (macrophage inflammatory protein-3α) is another chemokine that attracts human CD34 + cell-derived Langerhans cells in vitro 13 , but its role in vivo has not been clarified. One week after transplantation, CCL20, CCL2 and CCL7 transcript levels were 10, 17 and 13 times higher, respectively, in the skin of mice that received donor T cells compared with those that did not receive T cells (Fig. 3a) . CCL20 transcripts remained at similar levels 3 weeks after transplantation, whereas CCL2 and CCL7 decreased around 2 weeks after transplantation (data not shown).
CCR2 chemokine ligands facilitate Langerhans cell chimerism
Because alloreactive T cells induced the secretion of CCR2 ligands, including CCL2 and CCL7, we wanted to know whether these chemokines also had a role in the recruitment of donor-derived Langerhans cell precursors to the skin after allogeneic bone marrow transplantation. Mice reconstituted with 100% Ccr2 -/-bone marrow had Langerhans cell chimerism similar to that of mice reconstituted with Ccr2 +/+ bone marrow (Fig. 3b) . However, when mice were injected with a 1:1 mixture of Ccr2 -/-and Ccr2 +/+ TCD bone marrow and wild-type peripheral blood T cells, Ccr2 -/-Langerhans cells were undetectable in the skin for at least 12 weeks after bone marrow transplantation (Fig. 3c) , suggesting that CCR2 ligands facilitate but are not required for Langerhans cell recruitment to the skin after allogeneic bone marrow transplantation. 
CCR6 ligands are required for Langerhans cell chimerism
CCR6 is the only known receptor for CCL20 (ref. 13) . To analyze the role of CCL20 in Langerhans cell chimerism after allogeneic transplantation, we injected lethally irradiated BALB/c mice with Ccr6 -/-TCD bone marrow cells that are unable to respond to CCL20 chemokine gradients in vivo, together with wild-type peripheral blood T cells. Notably, 6 weeks after transplantation, mice reconstituted with Ccr6 +/+ TCD bone marrow had sixfold more donor Langerhans cells compared with mice reconstituted with Ccr6 -/-TCD bone marrow (Fig. 3d) . The difference in Langerhans cell chimerism between the two groups persisted 12 weeks after transplantation (Fig. 3d) . The chimerism defect associated with Ccr6 -/-or Ccr2 -/-bone marrow was limited to the Langerhans cell population, as both Ccr2 -/-and Ccr6 -/-bone marrow contributed to splenic dendritic cells, circulating monocytes, T cells (Fig. 3e,f) and B cells (data not shown) with the same efficiency as did wild-type bone marrow cells. Although skin-homing T cells express high levels of CCR6 and respond to CCL20 in vitro 14 , our results indicate that Ccr6 -/-and Ccr6 +/+ T cells were similarly able to infiltrate the skin of recipient mice and induce complete depletion of host Langerhans cells and recruitment of donor Langerhans cells ( Supplementary Fig. 1 online) . Both Ccr6 -/-and Ccr6 +/+ T cells were also able to induce skin GVHD (Supplementary Fig. 1 ). These results suggest that the defect of Langerhans cell chimerism observed in mice transplanted with Ccr6 -/-bone marrow is caused by defective Langerhans cell precursors, and that a similar defect in peripheral blood T cells does not interfere with the replacement of host Langerhans cells by donor Langerhans cells.
Role of host Langerhans cells in induction of skin GVHD
To explore the roles of host and donor Langerhans cells in skin GVHD, we reconstituted BALB/c mice with either TCD bone marrow or whole bone marrow from C57BL/6 mice. Although both groups had complete chimerism of white cells in the blood, as described above, Langerhans cell chimerism was achieved only in mice that received whole bone marrow. Eight weeks later, both groups were lethally irradiated again and injected with TCD bone marrow, together with peripheral blood T cells isolated from C57BL/6 mice. After this procedure, donor T cells progressively and selectively accumulated in the skin of mice that had persistent host Langerhans cells (Fig. 4a) . Five weeks after the second transplant, the percentage of T cells in the skin of those mice had increased by more than 15-fold. By contrast, in mice without host Langerhans cells, the percentage of T cells in skin declined to less than one-third of pretransplant levels. In addition, in mice with persistent host Langerhans cells, delayed administration of donor T cells resulted in the complete depletion of host Langerhans cells and induced the recruitment of donor Langerhans cells (Fig. 4b) . Most importantly, mice that had persistent host Langerhans cells before the second transplant developed marked (grade 4) skin GVHD (Fig. 4c) . By contrast, mice that had only donor Langerhans and dendritic cells in skindraining lymph nodes did not develop any skin lesions (Fig. 4d) .
To determine whether these results could be therapeutically exploited to protect against skin GVHD in patients, we exposed mice that were previously reconstituted with TCD bone marrow to ultraviolet light 11 . Forty-five days later, the mice underwent a second transplant with allogeneic TCD bone marrow and alloreactive T cells (Fig. 5a) . In mice previously reconstituted with TCD bone marrow and exposed to ultraviolet light, host Langerhans cells were almost completely depleted (0.15% epidermal cells) compared with mice not exposed to ultraviolet light (3.15% epidermal cells; Fig. 5b and Table 1 ). In mice that had not been reconstituted with TCD bone marrow, ultraviolet light induced the depletion of epidermal Langerhans cells (data not shown), followed by their replacement with endogenous bone marrow-derived Langerhans cells, which remained in the epidermis at the time of the second transplant ( Fig. 5b and data not  shown) . Notably, mice reconstituted with TCD bone marrow and not subsequently exposed to ultraviolet light, as well as ultraviolet-treated BALB/c mice that were not reconstituted with TCD bone marrow, developed severe skin GVHD (Fig. 5c,d and Table 1 ). By contrast, mice that were reconstituted with TCD bone marrow and then exposed to ultraviolet light developed little or no skin GVHD ( Fig. 5e and Table 1 ).
DISCUSSION
The failure of circulating hematopoietic precursors to replace host Langerhans cells in recipients of allogeneic bone marrow transplants was demonstrated in two different experimental models. First, Langerhans cells remained of host origin for at least 12 months after transplantation of a purified population of allogeneic HSCs. Second, more than 18 months after transplantation with allogeneic TCD bone marrow, Langerhans cells were not replaced by donor precursors, whereas all other DC populations, including liver, blood and dendritic cells in lymphoid organs, were of donor origin within 3 to 4 weeks. The difference between our results and those of earlier studies, which showed that Langerhans cells are rapidly replaced by donor-derived Langerhans cells after allogeneic bone marrow transplantation 15, 16 , seems to be related to the presence or absence of donor T cells in the bone marrow graft. When mice were reconstituted with purified stem cells or TCD bone marrow, host Langerhans cells were never replaced by donor precursors. By contrast, Langerhans cells were always replaced by donor precursors when whole bone marrow (which contains 2% mature T cells) was transplanted or when allogeneic T cells were added to TCD bone marrow grafts. Because whole allogeneic bone marrow was used in these earlier studies 15, 16 , the Langerhans cell chimerism that ensued was probably caused by the presence of donor T cells in the bone marrow allograft. Consistent with this interpretation, we found that the level of Langerhans cell chimerism increased with the dose of coadministered allogeneic T cells. Studies of Langerhans cell chimerism after allogeneic bone marrow transplantation are difficult in humans because of the lack of easily identifiable markers that distinguish donor from recipient Langerhans cells. Nonetheless, an elegant study analyzed Langerhans cell chimerism in eight children with MHC class II deficiency (bare lymphocyte syndrome) transplanted with allogeneic bone marrow, and searched for donor MHC II + Langerhans cells in the skin after transplantation 17 . Consistent with our findings, donor Langerhans cells were not detected in the two children reconstituted with TCD allogeneic bone marrow, despite unequivocal engraftment of donor cells in the peripheral blood and dermis, whereas donor Langerhans cells were found in children who received whole allogeneic bone marrow grafts. Although these results must be confirmed in a larger number of patients, they suggest that in humans as well as mice Langerhans cell chimerism after allogeneic bone marrow transplantation is induced only in the presence of alloreactive T cells.
We previously reported that the recruitment of circulating Langerhans cell precursors depends not only on available Langerhans cell sites in the epidermis, but also on the secretion of proinflammatory chemokines capable of attracting bone marrow-derived Langerhans cell precursors from the blood to the skin 11 . As shown in the current study, allogeneic T cells not only create available Langerhans cell sites by depleting host Langerhans cells, but also induce the secretion in the skin of proinflammatory chemokines including MCP and CCL20. Our results reveal for the first time an important role for CCL20 in the recruitment of host Langerhans cells in vivo. Low levels of donor Langerhans cells persisted for at least 12 weeks after transplantation of Ccr6 -/-TCD bone marrow, suggesting that the role of CCL20 in the trafficking of donor-derived Langerhans cell precursors to the skin is not redundant. CCL20 induces the migration of human CD34 + progenitor-derived Langerhans cells in vitro 13 , and CCL20 is increased in inflamed human skin 14 . A role for CCL20 in the recruitment of Langerhans cells would seem to be at odds with the finding that Ccr6 -/-mice have normal levels of Langerhans cells in their skin 18 . However, our observation that CCL20 is important for Langerhans cell recruitment to inflamed, but not to normal, skin seems to reconcile these findings. Although skin-homing T cells express high levels of CCR6 and respond to CCL20 in vitro 14 , we found that T cells, in contrast to Langerhans cell precursors, do not require CCR6 to infiltrate the skin. Consistent with our study of ultraviolet light-induced skin injury after congenic bone marrow transplantation 11 , Ccr2 -/-TCD bone marrow transplanted alone gave rise to wild-type levels of Langerhans cells. By contrast, when Ccr2 -/-TCD bone marrow was transplanted with an equal amount of Ccr2 +/+ TCD bone marrow, Ccr2 -/-progenitors consistently failed to give rise to Langerhans cells, indicating that Ccr2 -/-Langerhans cell precursors cannot compete with Ccr2 +/+ Langerhans cell precursors to occupy the limited number of Langerhans cell sites in skin. These results suggest that after allogeneic transplantation, the recruitment of donor Langerhans cells to recipient skin requires CCL20 chemokine induction in the skin and is facilitated by MCP chemokines. Cooperation of chemokines in the recruitment of leukocytes has previously been shown to be necessary for B cells to enter lymph nodes 19 . Entry of Langerhans cell precursors into inflamed skin seems to be another example of this phenomenon.
Several studies have shown that dendritic cells in different tissues can migrate to draining lymph nodes in the absence of inflammatory signals [20] [21] [22] [23] [24] . Langerhans cells are also thought to constitutively migrate to draining lymph nodes to give rise to lymph node dendritic cells [25] [26] [27] . This suggests that in the absence of Langerhans cell chimerism, host dendritic cells should be detectable in skindraining lymph nodes but not in other lymphoid tissues. Accordingly, 8 months after transplantation of TCD bone marrow alone, the frequency of host-derived dendritic cells in skindraining lymph nodes was as high as 20%, which is consistent with the reported frequency of dendritic cell-derived Langerhans cells in human lymph nodes, whereas host dendritic cells were absent in the other lymphoid tissues examined. In addition, no host Mice not previously reconstituted with TCD bone marrow but exposed to ultraviolet light (c) and mice previously reconstituted with TCD bone marrow, but not exposed to ultraviolet light (d), show extensive mononuclear infiltrates in superficial dermis that focally infiltrate epidermis, associated with necrotic keratinocytes and vacuolization of basal keratinocytes (grade 2 GVHD). Mice previously reconstituted with TCD bone marrow and exposed to ultraviolet light (e) lack infiltrates in skin, and show only rare necrotic keratinocytes (grade 0.5 GVHD).
dendritic cells were detected in the skin-draining lymph nodes of mice with complete Langerhans cell chimerism. Together, these results provide further evidence for the constitutive migration of Langerhans cells to draining lymph nodes. The observation that high levels of host Langerhans cells in the skin and high levels of host dendritic cells in skin-draining lymph nodes persist in mice after TCD bone marrow transplantation has important implications for the development of GVHD in patients who undergo this procedure. The results of the present study show that after allogeneic transplantation, dendritic cell chimerism in the blood does not correlate with dendritic cell chimerism in skin, suggesting that host dendritic cells may persist in patients after allogeneic bone marrow transplantation even if they are found to be fully chimeric in the blood. To test whether host tissue dendritic cells that persist in complete bone marrow and blood chimeric mice can have a role in GVHD, we administered donor T cells together with TCD bone marrow to mice with only host or donor Langerhans cells in the skin. Notably, the donor T cells induced skin GVHD in mice with persistent host Langerhans cells, but not in mice in which host Langerhans cells had already been replaced by donor Langerhans cells. Although these results provide the first direct evidence that host Langerhans cells induce GVHD, previous studies have shown that host dendritic cells are essential for both the activation 5, 6, 28 and effector phases of acute GVHD 29 . In the latter study, donor T cells induced GVHD only if host hematopoietic cells were present in target tissues 29 . In this regard, host Langerhans cells persisting in skin may be responsible for the continued activation of donor T cells and for the production of cytokines that are crucial for the tissue damage observed in GVHD 29 . We also found that in mice that had predominantly host Langerhans cells after reconstitution with allogeneic TCD bone marrow, exposure to ultraviolet light induced the depletion of host Langerhans cells and rendered the mice resistant to skin GVHD. By contrast, control mice in which the majority of Langerhans cells were of host origin developed severe GVHD. Protection against skin GVHD was not related to a nonspecific effect of ultraviolet light, as nontransplanted BALB/c mice developed severe skin GVHD after injection of allogeneic T cells despite their exposure to ultraviolet light.
Chronic GVHD with involvement of the skin is a common complication of allogeneic bone marrow transplantation 30 . Because we found that Langerhans cell replacement is dependent on the number of donor T cells present in the graft, varying degrees of Langerhans cell chimerism can be expected in bone marrow-transplanted patients. Indeed, host Langerhans cells have been found in the skin of patients more than 1 year after transplantation 31 . Phototherapy using ultraviolet light improves cutaneous lesions but not other lesions of chronic GVHD 30 . It will thus be interesting to determine whether the improvement of skin GVHD observed in phototherapy-treated patients is related to the induction of Langerhans cell chimerism in the skin.
Our results reveal new information about the cellular and molecular mechanisms leading to Langerhans cell chimerism after allogeneic bone marrow transplantation. Alloreactive T cells induce Langerhans cell chimerism through two successive checkpoints: Fas ligand-dependent depletion of host Langerhans cells, and induction in the skin of CCL20 and MCP inflammatory chemokines that cooperate in the recruitment of circulating donor Langerhans cells. Our demonstration that depletion of host Langerhans cells by ultraviolet light before injection of alloreactive T cells protects against skin GVHD establishes the basis for clinical trials testing the beneficial effect of ultraviolet light in patients who are candidates for allogeneic bone marrow transplants.
METHODS

Mice.
We purchased 5-to 7-week-old male C57BL/6 (CD45.2 + H-2 b ), C57BL/6 (CD45.1 + H-2 b ), C57BL/6 Fas ligand-defective (gld) mice 32 and C57BL/6 perforin-deficient (Prf1 -/-) 33 mice from The Jackson Laboratory. Seven-to eight-week-old male BALB/c (H-2 d ) mice were obtained from the Stanford University Department of Comparative Medicine. C57BL/6 Ccr6 -/-and C57BL/6 Ccr2 -/-mice were generated as described (refs. 18,34, respectively) . The Stanford University Committee on Animal Welfare approved all mouse protocols.
Cytokines and antibodies. We purchased recombinant mouse granulocytemacrophage colony-stimulating factor and tumor necrosis factor-α from PeproTech. We purchased all monoclonal antibodies from PharMingen, except the monoclonal antibody to Thy1.2, which we purchased from Caltag.
Allogeneic stem cell and bone marrow transplantation. We lethally irradiated BALB/c recipient mice with 800 rad using an X-ray source, then injected them intravenously with 1 × 10 3 purified HSCs, or 2 × 10 6 or 25 × 10 6 TCD bone marrow cells isolated from C57BL/6 mice. We purified HSCs using a protocol described elsewhere 35 . We obtained TCD bone marrow as described previously 36 . Where indicated, we lethally irradiated BALB/c mice (800 rad) and injected then with 25 × 10 6 whole bone marrow cells isolated from C57BL/6 mice.
Isolation of T cells.
We purified TCR-αβ + CD8 + CD4 + triple-positive and propidium iodide (PI)-negative cells from peripheral blood or spleen using a FACSVantage flow cytometer (Becton Dickinson). To prepare bone marrow T cells, we purified TCR-αβ + cells by FACS from an enriched Thy1.2 + bone marrow cell population. The purity of each T-cell preparation was >98%, as assessed by flow cytometry. We used a low dose of donor T cells (1.5 × 10 5 ) in most of the transplantation experiments to avoid early death due to acute GVHD, and to study the Langerhans cell chimerism that occurs mainly between 5 and 9 weeks after transplantation.
Isolation and characterization of skin cells. We isolated skin cells as described elsewhere 11 . We determined the percentage of epidermal cells that were hostderived (I-A d ) or donor-derived (I-A b ) Langerhans cells by flow cytometry, gating on CD45 + PI -epidermal cells. We determined the percentage of donor TCRαβ + skin-infiltrating T cells by gating on PI -skin cells.
Isolation of spleen, liver and lymph node dendritic cells. We harvested spleen, liver and lymph nodes and injected them with collagenase D (1 mg/ml; Boehringer Mannheim) for 45 min (spleen and lymph nodes) or 90 min (liver) at 37 °C. We resuspended digested organs in medium and layered the cells above a Nycoprep solution (Nycomed). We collected the enriched dendritic cells at the interface and determined the proportion of host and donor dendritic cells by flow cytometry, gating on CD11c + cells.
Histopathologic examination of tissues. We embedded formalin-fixed tissues in paraffin, cut them into 4-µm sections and stained them with H&E. We blindly coded all histopathology slides, and a pathologist graded the GVHD lesions as described 37 .
Quantitative analysis of chemokine RNA expression in the skin. We extracted total RNA from bulk homogenized skin cells. We quantitatively analyzed chemokines and cyclophilin transcripts by the fluorogenic SYBR green PCR assay, using an MX4000 Multiplex Quantitative PCR System (Stratagene). We normalized relative RNA levels to cyclophilin and expressed the results as a ratio of chemokine to cyclophilin, which allowed us to determine the fold increase of relative RNA levels between transplanted and nontransplanted BALB/c mice.
Transplantation of Ccr6 -/-or Ccr2 -/-cells. We reconstituted lethally irradiated BALB/c mice with TCD bone marrow cells that were Ccr6 -/-, Ccr6 +/+ , Ccr2 -/-or Ccr2 +/+ , or a 1:1 mixture of Ccr2 -/-CD45.2 + and Ccr2 +/+ CD45.1 + or Ccr2 +/+ CD45.2 + and Ccr2 +/+ CD45.1 + . We administered 2 × 10 6 TCD bone marrow cells either alone or in combination with wild-type peripheral blood T cells (all isolated from C57BL/6 mice). Where indicated, we injected BALB/c mice intra-venously with 2 × 10 6 TCD bone marrow cells isolated from wild-type CD45.1 + C57BL/6 mice, alone or in combination with peripheral blood T cells isolated from Ccr6 -/-or Ccr6 +/+ CD45.2 + C57BL/6 mice.
Repeat transplantation. We reconstituted lethally irradiated BALB/c mice (ten mice per group) with 2 × 10 6 TCD bone marrow cells or 25 × 10 6 whole bone marrow isolated from C57BL/6 mice. Eight weeks later, we lethally irradiated the mice again (800 rad) and injected them intravenously with 2 × 10 6 TCD bone marrow cells together with 2.5 × 10 5 spleen T cells isolated from C57BL/6 mice.
Induction of Langerhans cell chimerism before injection of allogeneic T cells.
In two separate experiments, we reconstituted groups of three or five BALB/c mice with TCD bone marrow or whole bone marrow. Two weeks after transplantation, we either left the transplanted mice untreated, or exposed transplanted and nontransplanted BALB/c mice to ultraviolet light (wavelength 254 nm, voltage 8 W, ultraviolet source 38 cm from the target) for 30 min. Three weeks later, we analyzed Langerhans cell chimerism in the epidermis by flow cytometry. Eight weeks after the first transplant (that is, 6 weeks after exposure to ultraviolet light), we lethally irradiated the mice (800 rad) again and reconstituted them with 5 × 10 6 TCD bone marrow cells together with 2 × 10 5 spleen T cells isolated from C57BL/6 mice.
Statistical analysis.
We compared GVHD scores between the treatment groups and tested the differences for statistical significance using the Student t test. We set the level of significance at P < 0.05. 
